Preparing for access to PRO 2000 microbicide
Report of a meeting (27–28 May 2009, London, United Kingdom)
Web only
NOTE:
Since this report was prepared, the results of the MDP 301 study were announced on 14 December 2009 and published in The Lanceton 20 September 2010. (http://dx.doi.org/10.1016/S0140-6736(10)61086-0). The study showed no benefit
of 0.5% PRO2000 in reducing the risk of HIV infection. All further development and investment in the product has ceased.
Overview
This report summarizes key elements of the meeting discussions: existing data and analysis plans from both the Microbicide Trials Network (MTN) and Microbicides Development Programme (MDP), and priorities for additional clinical research; ownership and licensing; cost; manufacturing; regulatory review; policy and programmes; strategic communications and messaging; and next steps. A chart and timeline summarizing the agreed action plan, roles and responsibilities, and timeframe are attached